Luqi Biology collaborates with clients on project design, implements tasks in their respective areas of expertise, and shares development risks, project costs, intellectual property, and profits.
Luqi Biology transfers development rights for products with advanced development to pharmaceutical clients, earning payments and revenue shares based on milestones achieved by the client.
Luqiu Bio reports completion of the first dosing in a Phase IIb trial of its inhaled IL-4Rα single-domain antibody LQ036 for uncontrolled asthma, led by Shanghai Jiaotong University-affiliated Ruijin Hospital.
Founded in October 2017, Luqi Biology employs around 90 staff and operates a 7,500+ square meter R&D and production base, including a camel breeding facility. It has developed five core nanobody-based technology platforms, including nanobody screening, *Pichia pastoris* CMC development, inhaled macromolecule drug development, long-acting nanobody, and nanobody bispecific platforms.
